In a March 31 report, Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:NGEN), saying the firm remains focused primarily on the company’s clinical progress rather than near-term financial results. Uddin said NervGen recently completed its end-of-Phase 2 meeting […]
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$3.50 target on Spectral Medical (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) following publication of the company’s TIGRIS septic shock study in The Lancet Respiratory Medicine. In a March 24 note, Uddin described the data as exceptionally strong after Spectral announced full […]
Share
Tweet
Share
